Evidence map›Paper›PMID 38577717›Full record

ArticleThe Journal of clinical endocrinology and metabolism2024

A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change.

Danilo Villagelin, David S Cooper, Henry B Burch

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Treatment outcomes in patients with relapsed Graves' disease.Archives of endocrinology and metabolism · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Danilo VillagelinMedical School, Pontifícia Universidade Católica de Campinas, Campinas 13034-685, SP, Brazil.ORCID 0000-0002-4173-7258
David S CooperDivision of Endocrinology, Diabetes, and Metabolism, The Johns Hopkins University School of Medicine, Baltimore 21287, MD, USA.ORCID 0000-0002-9406-6400
Henry B BurchDivision of Diabetes, Endocrinology, & Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda 20892, MD, USA.
Johns Hopkins University · USNational Institutes of Health · USPontifícia Universidade Católica de Campinas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextOver the past several decades, there have been indications of potential shifts in the diagnostic strategies, treatment, and monitoring of patients with Graves disease (GD).

objectiveTo evaluate current practices in managing GD and compare them to previous surveys.

methodsWe used a global online survey of endocrinologists to assess shifts in the diagnosis, monitoring, and treatment in a typical patient with GD, as well as treatment variation in 5 different clinical scenarios.

resultsA total of 1252 respondents from 85 countries completed the survey. Methods used to diagnose an uncomplicated GD case have changed over the past decade, reflecting increased use of thyrotropin receptor antibody (TRAb) and reciprocal decreases in nuclear medicine studies. The preferred mode of therapy for uncomplicated GD was antithyroid drugs (ATDs) by 91.5% of respondents, radioactive iodine (RAI) therapy by 7%, and thyroidectomy by 1.5%. Compared with previous surveys, the use of RAI as a first-line choice decreased in all geographic regions. The United States had the sharpest decline in the selection of initial therapy with RAI, decreasing from 69% in 1990 to 11.1% in 2023. In patients with persistent TRAb positivity after 18 months, 68.7% of respondents would continue the use of ATDs. After a relapse of GD, resumption of ATDs was selected by 59.9% of respondents. In patients with active thyroid eye disease or planning pregnancy, ATDs were the first choice (67.5% and 72.8%, respectively), and thyroidectomy emerged as the second choice (22.9% and 15.6%, respectively).

conclusionParadigm shifts have occurred in the management of uncomplicated GD and its variants, as well as the response to persistent and recurrent hyperthyroidism.

Indexed as

Antithyroid AgentsGraves DiseasePractice Patterns, Physicians'AdultDisease ManagementEndocrinologistsFemaleHumansIodine RadioisotopesMaleMiddle AgedPregnancySurveys and QuestionnairesThyroidectomyAntithyroid AgentsIodine Radioisotopesantithyroid drug therapyGraves diseasehyperthyroidismpregnancyradioiodine therapythyroid eye disease

Identifiers

PMID38577717
PMCPMC12102715
OpenAlexW4393991184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.